MP73-13 BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE

The Journal of Urology ◽

10.1016/j.juro.2015.02.2689 ◽

2015 ◽

Vol 193 (4S) ◽

Author(s):

Ken O'Day ◽

Cat N. Bui ◽

Scott Flanders ◽

Nina Oestreicher ◽

Peter Francis ◽

...

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Payer Perspective

Download Full-text

Budget impact analysis of enzalutamide for treatment of metastatic castration-resistant prostate cancer from a u.s. Payer perspective

Value in Health ◽

10.1016/j.jval.2015.03.1135 ◽

2015 ◽

Vol 18 (3) ◽

pp. A196

Author(s):

C.N. Bui ◽

K. O’Day ◽

S. Flanders ◽

N. Oestreicher ◽

P. Francis ◽

...

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Payer Perspective

Download Full-text

Abiraterone and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post Chemotherapy: An Indirect Comparison and Budget Impact Analysis

Value in Health ◽

10.1016/j.jval.2013.08.412 ◽

2013 ◽

Vol 16 (7) ◽

pp. A394

Author(s):

T. Li ◽

M. Thompson ◽

M. Todd ◽

M. Yu ◽

T. Kheoh ◽

...

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Indirect Comparison ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

PCN129 A COST-UTILITY AND BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) IN MEXICO

Value in Health ◽

10.1016/j.jval.2020.04.1619 ◽

2020 ◽

Vol 23 ◽

pp. S45-S46

Author(s):

W. Toro ◽

S. Braun ◽

L.A. Sanchez ◽

P. Anaya

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Cost Utility ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

A Dynamic Approach for Budget Impact Analysis (BIA) in Oncology: Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) as an Illustrative Example

Value in Health ◽

10.1016/j.jval.2018.04.1492 ◽

2018 ◽

Vol 21 ◽

pp. S220

Author(s):

CD Mullins ◽

H Le ◽

J Lawson ◽

F Pan

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Dynamic Approach ◽

Castration Resistant

Download Full-text

Radio-223 in the Treatment of Metastatic Castration Resistant Prostate Cancer with Bone Metastases: Budget Impact Analysis of the National Health Service

Value in Health ◽

10.1016/j.jval.2015.09.1086 ◽

2015 ◽

Vol 18 (7) ◽

pp. A442

Author(s):

S Di Matteo ◽

MC Valentino ◽

GM Bruno ◽

GL Colombo

Keyword(s):

Prostate Cancer ◽

National Health Service ◽

Health Service ◽

Bone Metastases ◽

National Health ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Budget Impact Analysis of Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel in the Mexican Public Healthcare System

Value in Health ◽

10.1016/j.jval.2018.04.130 ◽

2018 ◽

Vol 21 ◽

pp. S21

Author(s):

JG Gay ◽

NM Schultz ◽

S Braun

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Healthcare System ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Public Healthcare ◽

Castration Resistant Prostate Cancer ◽

Public Healthcare System ◽

Castration Resistant

Download Full-text

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2020.20330 ◽

2020 ◽

pp. 1-9 ◽

Author(s):

Sreevalsa Appukkuttan ◽

Ryan Farej ◽

LaStella Miles ◽

Molly Purser ◽

Lonnie Wen

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Budget Impact Analysis of the Introduction of New Therapeutic Agents for the Treatment of Metastatic Castration Resistant Prostate Cancer (MCRPC) Patients After Docetaxel Failure in the Brazilian Private Health System

Value in Health ◽

10.1016/j.jval.2014.08.2204 ◽

2014 ◽

Vol 17 (7) ◽

pp. A622

Author(s):

E. Asano ◽

V. Vitale

Keyword(s):

Prostate Cancer ◽

Health System ◽

Impact Analysis ◽

Budget Impact ◽

Therapeutic Agents ◽

Budget Impact Analysis ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Budget Impact Analysis of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with Docetaxel from the Perspective of the Brazilian Private Health Care System

Value in Health ◽

10.1016/j.jval.2013.08.1908 ◽

2013 ◽

Vol 16 (7) ◽

pp. A665 ◽

Author(s):

V. Vitale ◽

E. Asano ◽

M.L. Pereira

Keyword(s):

Prostate Cancer ◽

Health Care ◽

Cancer Patients ◽

Impact Analysis ◽

Budget Impact ◽

Abiraterone Acetate ◽

Private Health Care ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Previously Treated

Download Full-text

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2021.27.10.1377 ◽

2021 ◽

Vol 27 (10) ◽

pp. 1377-1387

Author(s):

Jinan Liu ◽

Carol Hawkes ◽

Lydia Walder ◽

Chloe Spalding ◽

Karin Travers ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Advanced Ovarian Cancer ◽

Budget Impact Analysis ◽

Payer Perspective

Download Full-text